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Cerebral cavernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that
can result in hemorrhagic stroke, seizures, recurrent headaches, and focal neurologic deficits. Mutations in the gene
KRIT1 are responsible for type 1 CCM (CCM1). We report that a novel gene, MGC4607, exhibits eight different
mutations in nine families with type 2 CCM (CCM2). MGC4607, similar to the KRIT1 binding partner ICAP1a,
encodes a protein with a phosphotyrosine-binding domain. This protein may be part of the complex pathway of
integrin signaling that, when perturbed, causes abnormal vascular morphogenesis in the brain, leading to CCM
formation.
Cerebral cavernous malformations (CCMs) are congen-
ital vascular anomalies of the CNS, with an incidence
in the general population of 0.1%–0.5% (Rigamonti et
al. 1988). The lesions are characterized by grossly en-
larged blood vessels consisting of a single layer of en-
dothelium and without any intervening neural tissue,
ranging in diameter from a few millimeters to several
centimeters (Rigamonti et al. 1988; Tomlinson et al.
1994; Gil-Nagel et al. 1995). CCMs usually present clin-
ically during the 3rd to 5th decade of life, resulting in
hemorrhagic stroke, seizures, recurrent headaches, and
focal neurologic deficits (Zabramski et al. 1994, 1999).
Magnetic resonance imaging (MRI) can detect these le-
sions and is often the only method to diagnose a clini-
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cally silent lesion. Familial forms of CCM are inherited
in an autosomal dominant fashion, with three known
loci on chromosomes 7q21.2 (CCM1 [MIM 116860])
(Dubovsky et al. 1995; Gunel et al. 1995; Marchuk et
al. 1995), 7p15-p13 (CCM2 [MIM 603284]) (Craig et
al. 1998), and 3q25.2-q27 (CCM3 [MIM 603285])
(Craig et al. 1998). The disease gene responsible for type
1 CCM (CCM1) encodes KRIT1 (KREV interaction
trapped 1) (Laberge et al. 1999; Sahoo et al. 1999), a
protein of unknown function containing four ankyrin
domains and a C-terminal FERM domain (Serebriiskii
et al. 1997). KRIT1 was recently shown to bind to
ICAP1a (integrin cytoplasmic domain-associated pro-
tein) (Zhang et al. 2001; Zawistowski et al. 2002), a
protein containing a phosphotyrosine-binding (PTB) do-
main that also binds to the b1-integrin cytoplasmic do-
main (Chang et al. 1997; Zhang and Hemler 1999). It
is not yet understood how mutations in KRIT1 lead to
the formation of CCMs, but the identification of the
causative genes for CCM2 and/or CCM3 may help to
elucidate the pathogenesis of CCMs.
A cohort of 37 probands with CCM was screened for
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Table 1
Characteristics of Nine Families with CCM2 Mutations
Family
No. of Affected
Individualsa Exon Nucleotide Change Mutation Consequence
Predicted Amino
Acid Change
2626 4 1 23delG Frameshift 8fsX22
214 1 1 30GrA Splicing alteration K10K
CAV01b 4 2 56delG Frameshift 19fsX22
70c 5 2 169_172delAGAC Frameshift 57fsX58
IFCAS-1d 4 2 169_172delAGAC Frameshift 57fsX58
229 4 4 314delT Frameshift 105fsX105
IFCAS-14 2 4 319CrT Nonsense Q107X
2030 5 6 610-1GrA Splicing alteration NA
2812 1 6 653delG Frameshift 218fsX291
a MRI positive and/or symptom positive.
b Data from Squitieri et al. 2000.
c Data from Steichen-Gersdorf et al. 1992.
d Data from Dupre et al. 2003.
Figure 1 Sequence traces of the eight CCM2 mutations. Each mutation is indicated by a black arrow. The extent of a 4-bp deletion is
shown with conjoined arrows.
KRIT1 mutations, and 10 harbored a KRIT1 mutation.
The 27 non-KRIT1 (CCM1) probands were included in
this study, and, where possible, additional family mem-
bers were collected. The boundaries of the CCM2 locus
were previously established by 1-LOD support analysis
as an 11-cM interval flanked by markers D7S2846 and
D7S1818 (Craig et al. 1998). Markers mapping within
the interval were used to haplotype several families with
CCM2, but no crossovers were identified in affected in-
dividuals. Since we were unable to genetically reduce the
size of the CCM2 interval, we began to sequence posi-
tional candidate genes.
Within the genetically defined interval, 55 known or
putative genes have been identified (UCSC Human Ge-
nome Assembly Web site). We initially selected eight
genes for sequence analysis on the basis of biological
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Figure 2 Northern blot analysis of MGC4607 expression. The
12 human tissues are indicated at the top, and size (in kb) is indicated
on the left.
Table 2
Comparison of MGC4607 Mutation Status with MRI Results
NO. OF FAMILY MEMBERS WITH A
MGC4607 MUTATION, WITH MRI STATUS
NO. OF FAMILY MEMBERS WITHOUT A
MGC4607 MUTATION, WITH MRI STATUS
FAMILY CCM Positive CCM Negative Unknown CCM Positive CCM Negative Unknown
2626 3 0 4a 0 0 6
214 1 0 1 0 2 1
CAV01b 4 0 0 0 0 1
70c 5 0 2 0 1 3
IFCAS-1d 4 0 1 0 0 10
229 4 1e 1 0 1 0
IFCAS-14 2 0 7 0 0 11
2030 5 0 2 0 1 15
2812 1 0 0 0 0 1
a One individual with stroke and seizures.
b Data from Squitieri et al. 2000.
c Data from Steichen-Gersdorf et al. 1992.
d Data from Dupre et al. 2003.
e One individual with stroke at age 20 years.
plausibility: MGC4607, RALA (v-ral simian leukemia
viral oncogene), CAMK2B (calcium/calmodulin-depen-
dent protein kinase II b), STK17A (serine/threonine ki-
nase 17a), CDC10 (cell division cycle 10 homolog),
CDC2L5 (cell division cycle 2–like 5), HIP-55 (src hom-
olog 3 domain–containing protein), and MYLC2A (my-
osin light chain 2a). The predicted gene MGC4607 was
chosen because its translated protein product encodes a
putative PTB domain. This same domain is found in
ICAP1a, a binding partner of the CCM1 product
KRIT1.
Among the panel of 27 probands without a KRIT1
mutation, we detected eight different mutations in
MGC4607. One mutation (169_172delAGAC) was
found in two separate families that—as a further inves-
tigation into ethnic background suggested—may be dis-
tantly related. The mutations include five frameshift, one
nonsense, and two splicing mutations (table 1; fig. 1),
each of which, if translated, would result in a truncated
protein. The mutations map throughout the gene, in-
cluding two in exon 1, suggesting that at least some may
lead to loss-of-function alleles.
One splice-junction mutation (610-1GrA, in family
2030) is located at the invariant G residue at the splice-
acceptor site adjacent to exon 6. A second splice-site
mutation was less obvious. Family 214 harbored what
appeared to be a silent mutation (30GrA; K10K) in the
last nucleotide of exon 1. Nonetheless, we thought that
this sequence alteration might also lead to a splicing
defect, because it results in a less favorable nucleotide
at this position of the donor splice junction and this
position is not infrequently a site of mutations affecting
splicing. Sequence analysis confirmed that the 30A var-
iant of MGC4607 was not present in 606 control chro-
mosomes. To examine its effect on the MGC4607
mRNA, we performed expression analysis on leukocyte
mRNA isolated from the proband. RT-PCR products
from both the proband and control leukocyte mRNA
exhibited a number of normal splice variants of the mes-
sage but no additional splice variants arising from the
patient mutation. However, sequence analysis of the RT-
PCR products from the proband revealed only the nor-
mal allele. This suggests that the mutant 30A allele is
not expressed or, more likely, that this mutation results
in a grossly aberrant splice variant that is subjected to
degradation.
Four of the families harboring MGC4607 mutations
were previously reported as consistent with showing
linkage to CCM2 (Craig et al. 1998; Squitieri et al. 2000;
Dupre et al. 2003). The remaining five families with
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Figure 3 Schematic diagram of malcavernin. Each exon is shown as a box with the corresponding exon number. The PTB domain is
shown in gray. The location and description of the eight CCM2 mutations are shown. Mutations affecting splice junctions are shown above,
with the introns indicated by lines.
CCM2 were of insufficient power to establish linkage.
Families not showing CCM2 mutations harbored either
mutations in the yet undiscovered CCM3 gene or mu-
tations undetectable by DNA sequence analysis of cod-
ing exons at the CCM1 and CCM2 loci.
The mutation in each of the nine families cosegregates
with affected status for all confirmed (MRI- and/or
symptom-positive) affected individuals (table 2). Except
for one individual from family 2626, all symptomatic
individuals had MRI data available that confirmed the
presence of the CCM lesions. One mutation carrier in
family 229 was apparently MRI negative at age 75 years
but had suffered a stroke of unknown etiology at age
20 years and thus was classified as “presumed affected.”
The families also contained a rather large number of
mutation carriers that were, at the time of ascertainment,
clinically silent (table 2). For nearly all of these, the lack
of overt symptoms led to a presumed unaffected status,
and, as a consequence, these individuals were not eval-
uated by MRI.
The large number of mutation-positive individuals
that remain asymptomatic provides an explanation for
the difficulty encountered in narrowing the candidate
interval for this and other CCM loci. Asymptomatic in-
dividuals will receive a medical diagnosis of unaffected,
but, without MRI examination, their status in terms of
genetic linkage analysis remains uncertain. The paucity
of confirmed affected individuals in most families pre-
cludes definitive linkage to a CCM locus and can even
mask the autosomal dominant inheritance. Even when
a family shows unequivocal linkage to the correct locus,
there are generally fewer confirmed affected (MRI-pos-
itive) family members and thus fewer informative mei-
oses that may harbor recombination events useful for
refined mapping.
These data confirm the previously noted reduced pen-
etrance within families with CCM with regard to ex-
pression of clinical symptoms. However, penetrance ap-
pears much higher in patients with MRI-diagnosed
affected status. A more accurate determination of pen-
etrance will require MRI examination of those individ-
uals who now test positive for the mutation in their
family. These data emphasize both the importance of
MRI in the diagnosis of CCM and the potential for
DNA-based diagnostics to identify those at risk.
To determine the expression pattern of MGC4607,
we performed northern blot analysis of human tissues,
using the entire cDNA as a probe (fig. 2). MGC4607 is
most highly expressed in the skeletal muscle, heart, and
liver, with minimal or no expression in the colon and
lung. MGC4607 is also expressed in the brain. KRIT1
and its binding partner, ICAP1a, have been also shown
to be expressed in the brain (Faisst and Gruss 1998;
Denier et al. 2002; Kehrer-Sawatzki et al. 2002). These
expression data suggest that CCM lesion formation may
not be due to an intrinsic vascular defect but, rather,
that the cerebral vasculature is aberrantly responding to
signals arising in the brain parenchyma. This is consis-
tent with the histopathology of the CCM lesions, which
are devoid of neuronal parenchyma within the lesions
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themselves. There are, however, other data that support
vascular expression of the CCM1 gene product KRIT1
(Gunel et al. 2002).
We have named this novel protein “malcavernin” for
its role in the development of cerebral cavernous mal-
formations (fig. 3). The identification of ICAP1a as a
KRIT1 binding partner (Zhang et al. 2001; Zawistowski
et al. 2002) suggested a model in which KRIT1 and b1-
integrin compete for ICAP1a binding, possibly regulat-
ing integrin signaling (Marchuk et al. 2003). The pres-
ence of a PTB domain in malcavernin predicts a possible
interaction with the CCM1 protein, KRIT1, and/or with
the b1-integrin cytoplasmic tail. Integrin signaling is crit-
ical for cell-cell and cell-extracellular matrix commu-
nication, which, in turn, modulates cellular migration
and morphology. A biochemical pathway is emerging
for CCM pathogenesis, involving regulation of integrin
signaling through a complex set of interacting proteins
that may compete for binding. The proteins involved in
this pathway include the CCM1 and CCM2 gene prod-
ucts KRIT1 and malcavernin.
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